Austin TR, McHugh CP, Brody JA, et al. Proteomics and Population Biology in the Cardiovascular Health Study (CHS): design of a study with mentored access and active data sharing. Eur J Epidemiol. 2022;37(7):755-765. doi:10.1007/s10654-022-00888-z
Wu CH, Tatavarty V, Beltran PMJ, et al. A bidirectional switch in the Shank3 phosphorylation state biases synapses toward up- or downscaling. Elife. 2022;11. doi:10.7554/eLife.74277
Krahmer N, Najafi B, Schueder F, et al. Organellar Proteomics and Phospho-Proteomics Reveal Subcellular Reorganization in Diet-Induced Hepatic Steatosis. Dev Cell. 2018;47(2):205-221.e7. doi:10.1016/j.devcel.2018.09.017
Qin W, Myers SA, Carey DK, Carr SA, Ting AY. Spatiotemporally-resolved mapping of RNA binding proteins via functional proximity labeling reveals a mitochondrial mRNA anchor promoting stress recovery. Nat Commun. 2021;12(1):4980. doi:10.1038/s41467-021-25259-2
Javasky E, Shamir I, Gandhi S, et al. Study of mitotic chromatin supports a model of bookmarking by histone modifications and reveals nucleosome deposition patterns. Genome Res. 2018;28(10):1455-1466. doi:10.1101/gr.230300.117
Brown EA, Lautz JD, Davis TR, et al. Clustering the autisms using glutamate synapse protein interaction networks from cortical and hippocampal tissue of seven mouse models. Mol Autism. 2018;9:48. doi:10.1186/s13229-018-0229-1
Huang J, Zhu H, Haggarty SJ, et al. Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc Natl Acad Sci U S A. 2004;101(47):16594-9. doi:10.1073/pnas.0407117101
Keshishian H, Burgess MW, Specht H, et al. Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry. Nat Protoc. 2017;12(8):1683-1701. doi:10.1038/nprot.2017.054
Udeshi ND, Mani DC, Satpathy S, et al. Rapid and deep-scale ubiquitylation profiling for biology and translational research. Nat Commun. 2020;11(1):359. doi:10.1038/s41467-019-14175-1
Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012;109(8):2860-5. doi:10.1073/pnas.1120589109